ESTRO 2024 - Abstract Book

S2647

Clinical - Urology

ESTRO 2024

with MCID for MHRT vs SBRT; UI was 187/511 (36.6%) vs 184/496 (37.1%), p=0.869; UO was 324/493 (65.7%) vs 336/478 (70.3%), p=0.127; bowel was 251/514 (48.8%) vs 287/488 (58.8%), p=0.002

Conclusion:

Despite an accelerated treatment schedule and a larger treated volume compared to PACE-B, RTOG assessments show similar rates of acute GI and GU toxicity for SBRT and MHRT. CTCAE and EPIC-26 bowel effects are more common after SBRT. Late toxicity and efficacy data are awaited.

Figure 1: RTOG toxicity (GI and GU) by time post-radiotherapy

Keywords: Prostate cancer, SBRT, Randomised controlled trial

3396

Proffered Paper

Focal boost SBRT in men with intermediate- and high-risk PCa: 5-year results of the hypo-FLAME trial

Cédric Draulans 1 , Karin Haustermans 1,2 , Floris J Pos 3 , Uulke A van der Heide 3 , Lisa De Cock 1 , Jochem RN van der Voort van Zyp 4 , Hans CJ de Boer 4 , Robert Jan Smeenk 5 , Martina Kunze-Busch 5 , Evelyn M Monninkhof 6 , Robin De Roover 2 , Sofie Isebaert 2 , Linda GW Kerkmeijer 4,5